Claudio Liguori1, Federico Paolini Paoletti2, Fabio Placidi3, Roberta Ruffini3, Giulia Maria Sancesario4, Paolo Eusebi2, Nicola Biagio Mercuri4,5, Lucilla Parnetti2. 1. Sleep Medicine Centre, Department of Systems Medicine, University of Rome 'Tor Vergata', Viale Oxford, 81 00133, Rome, Italy. dott.claudioliguori@yahoo.it. 2. Section of Neurology, Department of Medicine, University of Perugia, Perugia, Italy. 3. Sleep Medicine Centre, Department of Systems Medicine, University of Rome 'Tor Vergata', Viale Oxford, 81 00133, Rome, Italy. 4. IRCCS Fondazione Santa Lucia, Rome, Italy. 5. Neurology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
Abstract
PURPOSE OF REVIEW: Idiopathic REM sleep behavior disorder (iRBD) is one of the most significant prodromal manifestations of synucleinopathies. Different predictive biomarkers for iRBD conversion have been investigated, but scarce data are present in literature about the predictive role of cerebrospinal fluid (CSF) biomarkers. In this review, we focus on CSF biomarkers in patients with both iRBD and RBD associated with synucleinopathies to explore their potential predictive power. RECENT FINDINGS: Recent studies revealed that CSF α-synuclein levels are higher in Parkinson's disease (PD) patients with RBD compared to those without RBD, even if α-synuclein does not seem to predict conversion of iRBD into PD. In the Parkinson Progression Marker Initiative (PPMI) cohort, early PD patients with RBD show lower CSF Aβ42 levels, which predict faster cognitive decline. CSF prion protein and inflammatory biomarkers have been also investigated in RBD and synucleinopathies with controversial results. A variety of CSF biomarkers are promising candidate for predicting iRBD conversion into synucleinopathies. Further studies are needed in iRBD patients followed for several years in order to observe the phenoconversion in synucleinopathies and to elucidate the possible role of CSF biomarkers as predictive biomarkers of conversion.
PURPOSE OF REVIEW: Idiopathic REM sleep behavior disorder (iRBD) is one of the most significant prodromal manifestations of synucleinopathies. Different predictive biomarkers for iRBD conversion have been investigated, but scarce data are present in literature about the predictive role of cerebrospinal fluid (CSF) biomarkers. In this review, we focus on CSF biomarkers in patients with both iRBD and RBD associated with synucleinopathies to explore their potential predictive power. RECENT FINDINGS: Recent studies revealed that CSF α-synuclein levels are higher in Parkinson's disease (PD) patients with RBD compared to those without RBD, even if α-synuclein does not seem to predict conversion of iRBD into PD. In the Parkinson Progression Marker Initiative (PPMI) cohort, early PDpatients with RBD show lower CSF Aβ42 levels, which predict faster cognitive decline. CSF prion protein and inflammatory biomarkers have been also investigated in RBD and synucleinopathies with controversial results. A variety of CSF biomarkers are promising candidate for predicting iRBD conversion into synucleinopathies. Further studies are needed in iRBD patients followed for several years in order to observe the phenoconversion in synucleinopathies and to elucidate the possible role of CSF biomarkers as predictive biomarkers of conversion.
Authors: Yu Wang; Min Shi; Kathryn A Chung; Cyrus P Zabetian; James B Leverenz; Daniela Berg; Karin Srulijes; John Q Trojanowski; Virginia M-Y Lee; Andrew D Siderowf; Howard Hurtig; Irene Litvan; Mya C Schiess; Elaine R Peskind; Masami Masuda; Masato Hasegawa; Xiangmin Lin; Catherine Pan; Douglas Galasko; David S Goldstein; Poul Henning Jensen; Hui Yang; Kevin C Cain; Jing Zhang Journal: Sci Transl Med Date: 2012-02-15 Impact factor: 17.956
Authors: Alex Iranzo; Ana Fernández-Arcos; Eduard Tolosa; Mónica Serradell; José Luis Molinuevo; Francesc Valldeoriola; Ellen Gelpi; Isabel Vilaseca; Raquel Sánchez-Valle; Albert Lladó; Carles Gaig; Joan Santamaría Journal: PLoS One Date: 2014-02-26 Impact factor: 3.240
Authors: Jan O Aasly; Krisztina K Johansen; Gunnar Brønstad; Bjørg J Warø; Nour K Majbour; Shiji Varghese; Fatimah Alzahmi; Katerina E Paleologou; Dena A M Amer; Abdulmonem Al-Hayani; Omar M A El-Agnaf Journal: Front Aging Neurosci Date: 2014-09-25 Impact factor: 5.750
Authors: Michal Rolinski; Ludovica Griffanti; Paola Piccini; Andreas A Roussakis; Konrad Szewczyk-Krolikowski; Ricarda A Menke; Timothy Quinnell; Zenobia Zaiwalla; Johannes C Klein; Clare E Mackay; Michele T M Hu Journal: Brain Date: 2016-06-12 Impact factor: 13.501